top stories

White House names fi­nal­ists for Op­er­a­tion Warp Speed — with 5 ex­pect­ed names and one no­table omis­sion

1 hour ago
Coronavirus

UP­DAT­ED: Es­ti­mat­ing a US price tag of $5K per course, remde­sivir is set to make bil­lions for Gilead, says key an­a­lyst

4 hours ago
R&D
Pharma

Is a pow­er­house Mer­ck team prepar­ing to leap past Roche — and leave Gilead and Bris­tol My­ers be­hind — in the race ...

6 hours ago
R&D

A low-pro­file biotech bests Re­gen­eron in high-pro­file patent suit

4 hours ago
Pharma

Latest

Most read

Pfiz­er’s Doug Gior­dano has $500M — and some ad­vice — to of­fer a cer­tain breed of 'break­through' biotech

Yesterday
Venture

For­bion leads $62.5M round for neu­ro start­up as ex-Te­va R&D chief takes con­trol; CSL Behring inks gene ther­a­py pact ...

4 hours ago
Protocols

Bull­ish biotech mar­ket pro­pels Pli­ant to $144M IPO — as No­var­tis pro­vides a $10M boost

5 hours ago
IPOs

Cameron Dur­rant hus­tled his way from the OTC side­lines right in­to the Covid-19 drug race. Death or glo­ry lies ...

5 hours ago
People
Bioregnum

Covid-19 roundup: BAR­DA sup­ports Op­er­a­tion Warp Speed with big $628M con­tract to ser­vice Amer­i­ca's vac­cine pro­duc­tion ...

8 hours ago
Coronavirus

As NL­RP3 play­ers head for first clin­i­cal face-off, No­vo, Sanofi fu­el trans-At­lantic con­tender with $55M

8 hours ago
Venture
see latest stream
People

Why Mer­ck wait­ed, and what they now bring to the Covid-19 fight

Yesterday

Gilead woos fil­go­tinib clin­i­cal in­ves­ti­ga­tor from Stan­ford to lead the charge on NASH, in­flam­ma­to­ry dis­eases

Yesterday

Once a high fly­er, a stag­ger­ing Aduro is auc­tion­ing off most of the pipeline as CEO Stephen Isaacs hands off the ...

Yesterday
Startups

IPOs abound in the time of coro­n­avirus, as For­ma Ther­a­peu­tics pen­cils in $150M Nas­daq de­but

2 days ago

Ver­sant-backed, Bris­tol My­ers-stamped Re­pare Ther­a­peu­tics guns for $100M IPO

2 days ago

For a post-Soliris world, At­las-backed Q32 Bio out­lines $46M next-gen com­ple­ment play

Last week
Deals

Eyes on he­mo­phil­ia prize, Re­gen­eron adds a $100M wa­ger on joint de­vel­op­ment cam­paign with In­tel­lia

2 days ago

Gilead leas­es part­ner rights to TIG­IT, PD-1 in a $2B deal with Ar­cus. Now comes the hard part

Last week

In lat­est can­cer deal, Bris­tol My­ers Squib­b's new BD chief bets $65M in search for more tar­gets like PARP

Last week
IPOs

The big mon­ey: Poised to make drug R&D his­to­ry, a Chi­na biotech un­veils uni­corn rac­ing am­bi­tions in a bid to raise ...

3 days ago

As biotech IPOs siz­zle on vir­tu­al Wall Street, 3 new play­ers roll the dice on meg­a­money gam­bles top­ping $325M

Last week

A lit­tle-known biotech run­ning low on cash looks to get its own $100M IPO from pan­dem­ic mar­ket

2 weeks ago

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW
Subscribe to Endpoints News

Premium storiesSee all

Macro­Gen­ics CEO Scott Koenig gets the pre-AS­CO par­ty start­ed with some en­cour­ag­ing pipeline tid­bits — leav­ing lots ...

4 weeks ago
Bioregnum
R&D

Deal­mak­ing spiked to record lev­els in April as Covid-19 trig­gered a fever of part­ner­ing. But what hap­pens to ...

5 weeks ago
Deals

Full steam ahead, Pfiz­er goes bar­gain hunt­ing in an age of coro­n­avirus — with a spe­cial fo­cus on can­cer and rare ...

Last month
Bioregnum
R&D

A slice of half-baked remde­sivir da­ta takes a dark turn — but we're still wait­ing for a de­fin­i­tive study

Last month
Bioregnum
R&D

Don't missSee all

FDA de­lays de­ci­sion on No­var­tis’ po­ten­tial block­buster MS drug, wip­ing away pri­or­i­ty re­view

8 hours ago
R&D
Regulatory

Hill­house re­casts spot­light on Chi­na's biotech scene with $160M round for Shang­hai-based an­ti­body mak­er

Yesterday
Venture
China

Gilead re­leas­es an­oth­er round of murky remde­sivir re­sults

2 days ago
R&D

Covid-19 roundup: Did in­sid­ers cash in on pos­i­tive news re­port about Gilead be­fore pub­li­ca­tion?

2 days ago
Coronavirus

Endpoints Standouts

The 20 un­der 40: In­side the next gen­er­a­tion of bio­phar­ma lead­ers

Last month
People
Special

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

5 months ago
Special
Pharma

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

6 months ago
People
R&D

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron ...

7 months ago

Peer review See all

May
29

Sier­ra On­col­o­gy brings on for­mer Aim­mune CEO to the helm; Flag­ship woos ex-No­var­tis ex­ec Fab­rice Chouraqui

May
29

Sanofi brings in 4 new ex­ec­u­tives in con­tin­ued shake-up, as vac­cines and con­sumer health chief head out the door

May
29

Look­ing to move past an R&D fi­as­co, Ipsen poach­es their new CEO from Sanofi

May
22

The man who led Gilead’s au­toim­mune piv­ot heads to Boston; No­var­tis gets a new chief for its AI In­no­va­tion Cen­ter

May
15

Cher­ry Thomas joins Cari­bou as SVP of clin­i­cal de­vel­op­ment; Ar­tax locks in Joseph Lobac­ki as CEO

R&D channel feed

2 days ago

Bio­Marin holds the line on bleeds with 4-year val­rox up­date on he­mo­phil­ia A — but what's this about an­oth­er de­cline in Fac­tor 8 lev­els?

Bio­Marin has post­ed some top-line re­sults for their 4-year fol­lowup on the most ad­vanced gene ther­a­py for he­mo­phil­ia A — ex­tend­ing its streak on keep­ing a hand­ful of pa­tients free of ...

READ MORE

Bris­tol My­ers Squib­b's just-launched MS drug Zeposia makes the cut in key ul­cer­a­tive col­i­tis tri­al

Yesterday

Novus Ther­a­peu­tics plunges deep in­to pen­ny stock ter­ri­to­ry af­ter failed ear tri­al

Yesterday
latest in R&D

Iterum's fu­ture looks un­cer­tain, af­ter lead an­tibi­ot­ic fails con­sec­u­tive piv­otal stud­ies

2 days ago

Roche nabs front­line OK for Avastin/Tecen­triq in com­mon liv­er can­cer, best­ing an old Bay­er drug

2 days ago
Regulatory

My­ovant’s re­l­u­golix wins a piv­otal prostate can­cer show­down with an old stan­dard — com­ing down to the wire on ap­provals

2 days ago

In a sting­ing set­back, Pfiz­er’s can­cer block­buster Ibrance flops in key ad­ju­vant set­ting

3 days ago

Ab­b­Vie wins an ap­proval in uter­ine fi­broid-as­so­ci­at­ed heavy bleed­ing. Are ri­vals My­ovant and Ob­sE­va far be­hind?

5 days ago
Regulatory
see latest stories

Pharma channel feed

5 days ago

Pfiz­er, Mer­ck KGaA ce­ment Baven­cio blad­der can­cer win with OS da­ta — while carv­ing an­oth­er niche in rare can­cer

Pfiz­er and Mer­ck KGaA have de­tailed the Phase III da­ta that in­spired FDA reg­u­la­tors to des­ig­nate Baven­cio a “break­through” for first-line ad­vanced blad­der can­cer and of­fered an ear­ly ...

READ MORE

Cap­i­tal­iz­ing Pablo: The world’s biggest drug roy­al­ty buy­er is go­ing pub­lic. And the low-key CEO di­vulges a few ...

6 days ago
People

Bris­tol My­ers Squibb fi­nal­ly gets in the front­line NSCLC game dom­i­nat­ed by Mer­ck, adding a sec­ond Op­di­vo/Yer­voy-based ...

Last week
Regulatory
latest in Pharma

Ger­man Mer­ck bests US Mer­ck in UK copy­right tus­sle of Mer­ck v. Mer­ck

Last week

FDA ap­proves the first gener­ic for Amar­in's Vas­cepa — but is a fish oil price war im­mi­nent?

Last week
Regulatory

Parkin­son's pa­tients no longer need to re­ly on a nee­dle for apo­mor­phine an­ti­dote for 'of­f' episodes af­ter new FDA ap­proval

Last week
Regulatory

Once val­ued at $4B, an em­bat­tled Ako­rn — nurs­ing a mar­ket cap of rough­ly $37M — files for bank­rupt­cy

Last week
Regulatory

As­traZeneca, Mer­ck push block­buster fran­chise to an­oth­er key FDA ap­proval, rel­e­gat­ing a ri­val to sec­ond-fid­dle sta­tus

2 weeks ago
Regulatory
see latest stories

Coronavirus channel feed

Yesterday

Stephen Hahn: FDA will make some changes amid Covid-19 per­ma­nent

The FDA will look to per­ma­nent­ly im­ple­ment some of the process­es and poli­cies adopt­ed in its re­sponse to the Covid-19 pan­dem­ic, FDA com­mis­sion­er Stephen Hahn said dur­ing a vir­tu­al brief­ing ...

READ MORE

No­var­tis jumps in­to Covid-19 vac­cine hunt, as Big Phar­ma and big biotech com­mit to bil­lions of dos­es

6 days ago

Covid-19 roundup: FDA's Stephen Hahn per­son­al­ly helped a doc­tor set up hy­drox­y­chloro­quine tri­al — re­port

6 days ago
latest in Coronavirus

FDA ex­plains im­pact of Covid-19 on ap­pli­ca­tions, for­mal meet­ings

6 days ago
Regulatory

Ven­rock sur­vey shows grow­ing recog­ni­tion of coro­n­avirus toll, wan­ing con­fi­dence in ar­rival of vac­cines and treat­ments

6 days ago
R&D

Covid-19 roundup: Buoyed by soar­ing shares, No­vavax inks a $167M deal to buy Covid-19 vac­cine-mak­ing fa­cil­i­ty; France cools on hy­drox­y­chloro­quine

Last week

Biotech Voic­es: Coro­n­avirus will change biotech re­search with re­mote col­lab­o­ra­tions

Last week
Biotech Voices

Backed by BAR­DA, Mer­ck jumps in­to Covid-19: buy­ing out a vac­cine, part­ner­ing on an­oth­er and adding an­tivi­ral to the mix

Last week
R&D
see latest stories